Accelerating progress from advanced to early breast Cancer von Rugo, H.

Volltext

Immunotherapy toxicity: identification and management von Gumusay, O., Callan, J., Rugo, H. S.

Volltext

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 von Piccart, M., Hortobagyi, G.N., Campone, M., Pritchard, K.I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H.S., Deleu, I., Burris, H.A., Provencher, L., Neven, P., Gnant, M., Shtivelband, M., Wu, C., Fan, J., Feng, W., Taran, T., Baselga, J.

Volltext

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results f... von André, F., Ciruelos, E.M., Juric, D., Loibl, S., Campone, M., Mayer, I.A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., Inoue, K., Pápai, Z., Takahashi, M., Ghaznawi, F., Mills, D., Kaper, M., Miller, M., Conte, P.F., Iwata, H., Rugo, H.S.

Volltext

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up von Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., Mori, A., Gauthier, E. R., Bartlett, C. Huang, Gelmon, K. A., Slamon, D. J.

Volltext

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study von Adams, S., Schmid, P., Rugo, H.S., Winer, E.P., Loirat, D., Awada, A., Cescon, D.W., Iwata, H., Campone, M., Nanda, R., Hui, R., Curigliano, G., Toppmeyer, D., O’Shaughnessy, J., Loi, S., Paluch-Shimon, S., Tan, A.R., Card, D., Zhao, J., Karantza, V., Cortés, J.

Volltext

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study von Adams, S., Loi, S., Toppmeyer, D., Cescon, D.W., De Laurentiis, M., Nanda, R., Winer, E.P., Mukai, H., Tamura, K., Armstrong, A., Liu, M.C., Iwata, H., Ryvo, L., Wimberger, P., Rugo, H.S., Tan, A.R., Jia, L., Ding, Y., Karantza, V., Schmid, P.

Volltext

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer von Gennari, A., André, F., Barrios, C.H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S.A., Im, S.-A., Krug, D., Kunz, W.G., Loi, S., Penault-Llorca, F., Ricke, J., Robson, M., Rugo, H.S., Saura, C., Schmid, P., Singer, C.F., Spanic, T., Tolaney, S.M., Turner, N.C., Curigliano, G., Loibl, S., Paluch-Shimon, S., Harbeck, N.

Volltext

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis von Emens, L.A., Adams, S., Barrios, C.H., Diéras, V., Iwata, H., Loi, S., Rugo, H.S., Schneeweiss, A., Winer, E.P., Patel, S., Henschel, V., Swat, A., Kaul, M., Molinero, L., Patel, S., Chui, S.Y., Schmid, P.

Volltext

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial von Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., Roché, H., Im, Y.-H., Eiermann, W., Quek, R.G.W., Usari, T., Lanzalone, S., Czibere, A., Blum, J.L., Martin, M., Ettl, J.

Volltext

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from... von Geyer, C.E., Sikov, W.M., Huober, J., Rugo, H.S., Wolmark, N., O’Shaughnessy, J., Maag, D., Untch, M., Golshan, M., Lorenzo, J. Ponce, Metzger, O., Dunbar, M., Symmans, W.F., Rastogi, P., Sohn, J.H., Young, R., Wright, G.S., Harkness, C., McIntyre, K., Yardley, D., Loibl, S.

Volltext

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial von Rugo, H.S., Diéras, V., Gelmon, K.A., Finn, R.S., Slamon, D.J., Martin, M., Neven, P., Shparyk, Y., Mori, A., Lu, D.R., Bhattacharyya, H., Bartlett, C.H.u.a.n.g., Iyer, S., Johnston, S., Ettl, J., Harbeck, N.

Volltext

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer von Bardia, A., Tolaney, S.M., Punie, K., Loirat, D., Oliveira, M., Kalinsky, K., Zelnak, A., Aftimos, P., Dalenc, F., Sardesai, S., Hamilton, E., Sharma, P., Recalde, S., Gil, E.C., Traina, T., O’Shaughnessy, J., Cortes, J., Tsai, M., Vahdat, L., Diéras, V., Carey, L.A., Rugo, H.S., Goldenberg, D.M., Hong, Q., Olivo, M., Itri, L.M., Hurvitz, S.A.

Volltext

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced br... von Rugo, H.S., André, F., Yamashita, T., Cerda, H., Toledano, I., Stemmer, S.M., Jurado, J.C., Juric, D., Mayer, I., Ciruelos, E.M., Iwata, H., Conte, P., Campone, M., Wilke, C., Mills, D., Lteif, A., Miller, M., Gaudenzi, F., Loibl, S.

Volltext

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and... von Aapro, M., Rugo, H., Rossi, G., Rizzi, G., Borroni, M.E., Bondarenko, I., Sarosiek, T., Oprean, C., Cardona-Huerta, S., Lorusso, V., Karthaus, M., Schwartzberg, L., Grunberg, S.

Volltext

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 von Rugo, H.S., Pritchard, K.I., Gnant, M., Noguchi, S., Piccart, M., Hortobagyi, G., Baselga, J., Perez, A., Geberth, M., Csoszi, T., Chouinard, E., Srimuninnimit, V., Puttawibul, P., Eakle, J., Feng, W., Bauly, H., El-Hashimy, M., Taran, T., Burris, H.A.

Volltext

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the... von Ettl, J., Quek, R.G.W., Lee, K.-H., Rugo, H.S., Hurvitz, S., Gonçalves, A., Fehrenbacher, L., Yerushalmi, R., Mina, L.A., Martin, M., Roché, H., Im, Y.-H., Markova, D., Bhattacharyya, H., Hannah, A.L., Eiermann, W., Blum, J.L., Litton, J.K.

Volltext

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer von Rugo, H.S., Bianchini, G., Cortes, J., Henning, J.-W., Untch, M.

Volltext

Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer von Adams, S., Diéras, V., Barrios, C.H., Winer, E.P., Schneeweiss, A., Iwata, H., Loi, S., Patel, S., Henschel, V., Chui, S.Y., Rugo, H.S., Emens, L.A., Schmid, P.

Volltext

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study von Rugo, H.S., O’Shaughnessy, J., Boyle, F., Toi, M., Broom, R., Blancas, I., Gumus, M., Yamashita, T., Im, Y.-H., Rastogi, P., Zagouri, F., Song, C., Campone, M., San Antonio, B., Shahir, A., Hulstijn, M., Brown, J., Zimmermann, A., Wei, R., Johnston, S.R.D., Reinisch, M., Tolaney, S.M.

Volltext